[New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].

Pasquier, Corentin; Basse, Clémence

[New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer]. / Nouvelles AMMs : lorlatinib dans le traitement des cancers bronchiques non à petites cellules avec translocation ALK en première ligne.

Pasquier, Corentin; Basse, Clémence.

Affiliation

Pasquier C; Institut universitaire du cancer de Toulouse - Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. Electronic address: pasquier.corentin@iuct-oncopole.fr.
Basse C; Institut du Thorax Curie Montsouris, Institut Curie, Paris, France.

Bull Cancer ; 109(9): 877-878, 2022 09.

Article in Fr | MEDLINE | ID: mdl-35717222

Subject(s)

Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Aminopyridines/therapeutic use; Carcinoma, Non-Small-Cell Lung/drug therapy; Drug Approval; Humans; Lactams; Lactams, Macrocyclic/therapeutic use; Lung Neoplasms/drug therapy; Protein Kinase Inhibitors/therapeutic use; Pyrazoles; Receptor Protein-Tyrosine Kinases

Key words

ALK; Cancer bronchique non à petites cellules; Lorlatinib; Non-small cell lung cancer; Targeted therapies; Thérapies ciblées

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Lung Neoplasms Limits: Humans Language: Fr Journal: Bull Cancer Year: 2022 Document type: Article Country of publication: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google